• Je něco špatně v tomto záznamu ?

Global scales for cognitive screening in Parkinson's disease: Critique and recommendations

M. Skorvanek, JG. Goldman, M. Jahanshahi, C. Marras, I. Rektorova, B. Schmand, E. van Duijn, CG. Goetz, D. Weintraub, GT. Stebbins, P. Martinez-Martin, members of the MDS Rating Scales Review Committee,

. 2018 ; 33 (2) : 208-218. [pub] 20171123

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028689

BACKGROUND: Cognitive impairment is a common nonmotor manifestation of Parkinson's disease, with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive domains to severe dementia. The International Parkinson and Movement Disorder Society commissioned the assessment of the clinimetric properties of cognitive rating scales measuring global cognitive performance in PD to make recommendations regarding their use. METHODS: A systematic literature search was conducted to identify the scales used to assess global cognitive performance in PD, and the identified scales were reviewed and rated as "recommended," "recommended with caveats," "suggested," or "listed" by the panel using previously established criteria. RESULTS: A total of 12 cognitive scales were included in this review. Three scales, the Montreal Cognitive Assessment, the Mattis Dementia Rating Scale Second Edition, and the Parkinson's Disease-Cognitive Rating Scale, were classified as "recommended." Two scales were classified as "recommended with caveats": the Mini-Mental Parkinson, because of limited coverage of executive abilities, and the Scales for Outcomes in Parkinson's Disease-Cognition, which has limited data on sensitivity to change. Six other scales were classified as "suggested" and 1 scale as "listed." CONCLUSIONS: Because of the existence of "recommended" scales for assessment of global cognitive performance in PD, this task force suggests that the development of a new scale for this purpose is not needed at this time. However, global cognitive scales are not a substitute for comprehensive neuropsychological testing. © 2017 International Parkinson and Movement Disorder Society.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028689
003      
CZ-PrNML
005      
20190823104858.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/mds.27233 $2 doi
035    __
$a (PubMed)29168899
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Skorvanek, Matej $u Department of Neurology, Safarik University, Kosice, Slovakia. Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia.
245    10
$a Global scales for cognitive screening in Parkinson's disease: Critique and recommendations / $c M. Skorvanek, JG. Goldman, M. Jahanshahi, C. Marras, I. Rektorova, B. Schmand, E. van Duijn, CG. Goetz, D. Weintraub, GT. Stebbins, P. Martinez-Martin, members of the MDS Rating Scales Review Committee,
520    9_
$a BACKGROUND: Cognitive impairment is a common nonmotor manifestation of Parkinson's disease, with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive domains to severe dementia. The International Parkinson and Movement Disorder Society commissioned the assessment of the clinimetric properties of cognitive rating scales measuring global cognitive performance in PD to make recommendations regarding their use. METHODS: A systematic literature search was conducted to identify the scales used to assess global cognitive performance in PD, and the identified scales were reviewed and rated as "recommended," "recommended with caveats," "suggested," or "listed" by the panel using previously established criteria. RESULTS: A total of 12 cognitive scales were included in this review. Three scales, the Montreal Cognitive Assessment, the Mattis Dementia Rating Scale Second Edition, and the Parkinson's Disease-Cognitive Rating Scale, were classified as "recommended." Two scales were classified as "recommended with caveats": the Mini-Mental Parkinson, because of limited coverage of executive abilities, and the Scales for Outcomes in Parkinson's Disease-Cognition, which has limited data on sensitivity to change. Six other scales were classified as "suggested" and 1 scale as "listed." CONCLUSIONS: Because of the existence of "recommended" scales for assessment of global cognitive performance in PD, this task force suggests that the development of a new scale for this purpose is not needed at this time. However, global cognitive scales are not a substitute for comprehensive neuropsychological testing. © 2017 International Parkinson and Movement Disorder Society.
650    _2
$a zvířata $7 D000818
650    _2
$a kognitivní poruchy $x diagnóza $x etiologie $7 D003072
650    _2
$a lidé $7 D006801
650    12
$a neuropsychologické testy $7 D009483
650    _2
$a Parkinsonova nemoc $x komplikace $7 D010300
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Goldman, Jennifer G $u Rush University Medical Center, Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Chicago, Illinois, USA.
700    1_
$a Jahanshahi, Marjan $u Sobell Department of Motor Neuroscience & Movement Disorders and the National Hospital for Neurology & Neurosurgery, London, UK.
700    1_
$a Marras, Connie $u Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.
700    1_
$a Rektorova, Irena $u Applied Neuroscience Research Group, Central European Institute of Technology, CEITEC, Masaryk University, Brno, Czech Republic.
700    1_
$a Schmand, Ben $u Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a van Duijn, Erik $u Department of Psychiatry, Leiden University Medical Centre, Leiden, and Centre of Mental Health Care Delfland, Delft, Netherlands.
700    1_
$a Goetz, Christopher G $u Rush University Medical Center, Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Chicago, Illinois, USA.
700    1_
$a Weintraub, Daniel $u Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania and Parkinson's Disease and Mental Health Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
700    1_
$a Stebbins, Glenn T $u Rush University Medical Center, Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Chicago, Illinois, USA.
700    1_
$a Martinez-Martin, Pablo $u National Centre of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.
710    2_
$a members of the MDS Rating Scales Review Committee
773    0_
$w MED00003420 $t Movement disorders : official journal of the Movement Disorder Society $x 1531-8257 $g Roč. 33, č. 2 (2018), s. 208-218
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29168899 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823105112 $b ABA008
999    __
$a ok $b bmc $g 1433838 $s 1067149
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 33 $c 2 $d 208-218 $e 20171123 $i 1531-8257 $m Movement disorders $n Mov Disord $x MED00003420
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace